Video: How many PD-1/L1 drugs do we need? Where is im­munother­a­py head­ed? Watch Jay Brad­ner, Hervé Hop­penot, Ellen Si­gal, David Berman, Gideon Blu­men­thal, and Aiman Sha­l­abi dis­cuss with End­points at #JPM18

SAN FRAN­CIS­CO —  In front of a packed house on Tues­day at the End­points News break­fast pan­el dur­ing #JPM18, Aiman Sha­l­abi, CMO at the Can­cer Re­search In­sti­tute kicked pro­ceed­ings off with his re­search on the ex­plod­ing PD-1/L1 pipeline, con­tin­u­ing on through the num­ber of can­cer im­munother­a­py prod­ucts his group is track­ing.

That’s a lot of pos­si­ble re­dun­dan­cy and in­ef­fi­cien­cies, Sha­l­abi said. And just how can we har­ness all this ef­fort in the most ef­fi­cient man­ner?

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN